CD74 Antibody (In-1): sc-19627
- CD74 Antibody (In-1) is a rat monoclonal IgG2b, cited in 1 publications, provided at 200 µg/ml
- recommended for detection of CD74 of mouse origin by WB, IP, IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- See CD74 (LN-2): sc-6262 for CD74 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD74 Antibody (In-1). This work is in progress.
QUICK LINKS
SEE ALSO...
CD74 Antibody (In-1) is a rat monoclonal IgG2b antibody that detects CD74 in mouse samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD74, also known as the invariant chain, plays a crucial role in the immune system by regulating the loading of peptides onto major histocompatibility complex class II (MHC II) molecules. This process is vital for the proper presentation of antigens to T lymphocytes, which is essential for initiating adaptive immune responses. The interaction between CD74 and MHC II occurs during the transport of MHC II to the endosomal compartment, where peptide binding takes place. CD74 is expressed on various immune cells, including B lymphocytes, where CD74 is found regardless of the histocompatibility leukocyte antigen (HLA) phenotype, while a subset of peripheral T lymphocytes that lack MHC II do not express CD74. The presence of CD74 on immune cells highlights CD74′s importance in maintaining immune homeostasis and facilitating effective immune responses, making anti-CD74 antibody (In-1) a valuable tool for researchers studying immune function and related disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD74 Antibody (In-1) References:
- CD74-NRG1 fusions in lung adenocarcinoma. | Fernandez-Cuesta, L., et al. 2014. Cancer Discov. 4: 415-22. PMID: 24469108
- CD74 ablation rescues type 2 diabetes mellitus-induced cardiac remodeling and contractile dysfunction through pyroptosis-evoked regulation of ferroptosis. | Chen, L., et al. 2022. Pharmacol Res. 176: 106086. PMID: 35033649
- CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. | Werr, L., et al. 2022. Mol Cancer Ther. 21: 821-830. PMID: 35247925
- Infection and inflammation stimulate expansion of a CD74+ Paneth cell subset to regulate disease progression. | Balasubramanian, I., et al. 2023. EMBO J. 42: e113975. PMID: 37718683
- CD74 deficiency reduces trophoblast invasion and proliferation mediated by SIRT1 in preeclampsia. | Liu, Z., et al. 2023. Reproduction. 166: 423-435. PMID: 37796743
- CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations. | Li, W., et al. 2024. J Thorac Oncol. 19: 613-625. PMID: 38070598
- CD74 Promotes Cyst Growth and Renal Fibrosis in Autosomal Dominant Polycystic Kidney Disease. | Zhou, JX., et al. 2024. Cells. 13: PMID: 38534333
- CD74 is a functional MIF receptor on activated CD4+ T cells. | Zhang, L., et al. 2024. Cell Mol Life Sci. 81: 296. PMID: 38992165
- Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer. | Wang, Z., et al. 2024. J Immunother Cancer. 12: PMID: 39107132
- CD74 facilitates immunotherapy response by shaping the tumor microenvironment of hepatocellular carcinoma. | Cheng, J., et al. 2024. Mol Med. 30: 116. PMID: 39118044
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD74 Antibody (In-1) | sc-19627 | 200 µg/ml | $322.00 | |||
CD74 Antibody (In-1) FITC | sc-19627 FITC | 200 µg/ml | $336.00 | |||
CD74 Antibody (In-1) PE | sc-19627 PE | 200 µg/ml | $349.00 |